Ribo Advances Metabolic Health with New Clinical Trial Application for siRNA RBD3133

In a significant stride for treating obesity-related health issues, Suzhou Ribo Life Science (06938.HK) along with its subsidiary Ribocure Pharmaceuticals AB, has formally submitted a Phase Ⅰ Clinical Trial Application (CTA) in the European Union for RBD3133—a groundbreaking small interfering RNA (siRNA) therapeutic. This innovative treatment specifically targets INHBE (inhibin subunit beta E), potentially revolutionizing how obesity and its associated metabolic disorders are managed.

Obesity is increasingly recognized as a worldwide health crisis that impacts over a billion individuals, leading to numerous related complications, including type 2 diabetes, cardiovascular disease, and other serious conditions. Despite recent advancements in the treatment landscape, there exists a critical demand for novel therapies that tackle the root causes of metabolic dysfunction and offer long-term clinical improvements.

The pivotal RBD3133 is engineered to silence the INHBE gene, which encodes the activin E protein. Genetic research indicates that individuals with natural loss-of-function variations in this gene benefit from healthier fat distribution and improved metabolic profiles, coupled with a reduced risk of conditions like coronary heart disease and type 2 diabetes. These findings suggest a promising avenue for therapeutic intervention in obesity and its metabolic ramifications.

The Phase Ⅰ study entails a randomized, placebo-controlled approach to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD3133, administered subcutaneously to individuals classified as overweight or obese. This study will mark the first instance of evaluating RBD3133 in humans, laying the groundwork for its ongoing clinical development.

Dr. Anders Gabrielsen, Chief Medical Officer of Ribo, stated, "This CTA submission is a clear advance for our cardiometabolic pipeline, underscoring our ability to harness compelling human genetic data into cutting-edge RNAi treatments."

The advent of RBD3133 symbolizes a crucial milestone in Ribo's siRNA development efforts targeting cardiovascular and metabolic diseases. It is anticipated to serve as a foundational treatment for disorders related to weight loss and its cardiovascular and metabolic implications. As Ribo's inaugural foray into the obesity therapy domain, RBD3133 highlights the company's strategic commitment to developing innovative medicines aimed at addressing extensive public health needs.

About Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB

Suzhou Ribo Life Science Co. Ltd. (Ribo, 06938.HK) is dedicated to the global advancement and commercialization of siRNA-based therapeutics. Utilizing its robust, vertically integrated technology platforms, Ribo has cultivated an extensive pipeline targeting major disease areas, encompassing cardiovascular and metabolic disorders, as well as liver and kidney diseases. Through relentless innovation, Ribo strives to deliver transformative siRNA treatment options to a global patient base. To learn more, please visit www.ribolia.com.

Ribocure Pharmaceuticals AB operates as the overseas arm of Suzhou Ribo Life Science, concentrating on developing life-saving oligonucleotide therapies. Their focus includes expanding their asset pipeline, exploring new target concepts, bolstering capacities for clinical trial execution, and developing siRNA drugs to meet pressing global medical needs. More information can be found at www.ribocure.com.